Market revenue in 2023 | USD 2,071.9 million |
Market revenue in 2030 | USD 5,698.7 million |
Growth rate | 15.6% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 80.72% in 2023. Horizon Databook has segmented the France precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The healthcare system in France relies heavily on government funds and national healthcare insurance. In 2015, a French Plan for Genomic Medicine 2025 was licensed. This plan was further developed and streamlined in 2016 by the French National Alliance for Life Sciences and Health (Aviesan). It was designed to facilitate the integration of genomic medicine in healthcare.
The plan also aims at establishing a genomic medicine industry that penetrates across France, boosting economic growth and innovation. Approximately USD 822 million had been invested in the first 5 years, with more than USD 200 million anticipated to be recovered from the industry. The initiative focuses on positioning France as a leading player in the precision and personalized medicine space by integrating genomic medicine into healthcare.
Furthermore, Human Precision MEDicine (Hu-PreciMED) project was launched by Intersystem & Oncodesign and is aimed at structuring the precision medicine industry in France. It includes over 45 medical and digital companies. Cap Digital and Medicen Paris Region are the prominent players that support advancements in this project.
Horizon Databook provides a detailed overview of country-level data and insights on the France precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into France precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account